Coronary Artery Outcomes in Kawasaki Disease by Treatment Day Within 10 Days of Fever Onset

被引:0
作者
Karandikar, Vedika M. [1 ]
Khan, Huthaifah [1 ]
Kim, Kwang-Youn A. [2 ]
Kociolek, Larry K. [1 ,3 ]
Jhaveri, Ravi [1 ,3 ]
Shulman, Stanford T. [1 ,3 ]
Rowley, Anne H. [1 ,3 ,4 ]
机构
[1] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA
[4] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 07期
基金
美国国家卫生研究院;
关键词
coronary artery aneurysms; Kawasaki disease; treatment day; treatment outcomes; coronary artery Z-scores; RISK-FACTORS; ABNORMALITIES; CHILDREN; DIAGNOSIS;
D O I
10.1093/ofid/ofae352
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Kawasaki disease (KD) is an acute febrile illness of childhood that can lead to coronary artery aneurysms (CAAs) and myocardial infarction. Intravenous immunoglobulin reduces the prevalence of CAA when given to patients with KD within 10 days of fever onset. Children with KD may undergo evaluation for other diagnoses before treatment, particularly those with incomplete KD criteria. If KD outcomes are improved with early treatment, a delay in treatment while evaluating for other causes might place these patients at risk. Methods We performed a retrospective cohort study of children treated for KD within the first 10 days of illness at our KD center from 2014 to 2021 to determine the prevalence of CAA by day of treatment. Results A total of 290 patients met the study criteria. No statistically significant difference was found in the odds of developing a maximum z score >= 2.5 for each day of delayed treatment within 10 days of fever onset (adjusted odds ratio, 0.87; 95% CI, .72-1.05; P = .13). Subgroup analyses by age, sex, and year of treatment did not reveal a significant association between treatment day and maximum z score >= 2.5, although the number of patients <6 months of age was small. Conclusions Our study supports current recommendations. We found similar odds of developing adverse coronary outcomes regardless of treatment day within 10 days from fever onset.
引用
收藏
页数:6
相关论文
共 22 条
  • [1] Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review
    Chiang, Ming-Hsiu
    Liu, Hsingjin Eugene
    Wang, Jinn-Li
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (07) : 662 - 667
  • [2] Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease
    Dallaire, Frederic
    Fortier-Morissette, Zoe
    Blais, Samuel
    Dhanrajani, Anita
    Basodan, Dania
    Renaud, Claudia
    Mathew, Mathew
    De Souza, Astrid M.
    Dionne, Audrey
    Blanchard, Joel
    Saulnier, Harrison
    Kaspy, Kimberley
    Rached-d'Astous, Soha
    Dandah, Nagib
    McCrindle, Brian W.
    Human, Derek G.
    Scuccimarri, Rosie
    [J]. PEDIATRICS, 2017, 139 (06)
  • [3] Preventing Coronary Artery Abnormalities: A Need for Earlier Diagnosis and Treatment of Kawasaki Disease
    Dominguez, Samuel R.
    Anderson, Marsha S.
    El-Adawy, Mohammed
    Glode, Mary P.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (12) : 1217 - 1220
  • [4] Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis
    Friedman, Kevin G.
    Gauvreau, Kimberlee
    Baker, Annette
    Son, Mary Beth
    Sundel, Robert
    Dionne, Audrey
    Giorgio, Thomas
    De Ferranti, Sarah
    Newburger, Jane W.
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (03) : 247 - +
  • [5] JCS/JS']JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease
    Fukazawa, Ryuji
    Kobayashi, Junjiro
    Ayusawa, Mamoru
    Hamada, Hiromichi
    Miura, Masaru
    Mitani, Yoshihide
    Tsuda, Etsuko
    Nakajima, Hiroyuki
    Matsuura, Hiroyuki
    Ikeda, Kazuyuki
    Nishigaki, Kazuhiko
    Suzuki, Hiroyuki
    Takahashi, Kei
    Suda, Kenji
    Kamiyama, Hiroshi
    Onouchi, Yoshihiro
    Kobayashi, Tohru
    Yokoi, Hiroyoshi
    Sakamoto, Kisaburo
    Ochi, Masami
    Kitamura, Soichiro
    Hamaoka, Kenji
    Senzaki, Hideaki
    Kimura, Takeshi
    [J]. CIRCULATION JOURNAL, 2020, 84 (08) : 1348 - 1407
  • [6] Increased Incidence of Incomplete Kawasaki Disease at a Pediatric Hospital After Publication of the 2004 American Heart Association Guidelines
    Ghelani, Sunil J.
    Sable, Craig
    Wiedermann, Bernhard L.
    Spurney, Christopher F.
    [J]. PEDIATRIC CARDIOLOGY, 2012, 33 (07) : 1097 - 1103
  • [7] What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis
    Jia, Xinyi
    Du, Xiao
    Bie, Shuxian
    Li, Xiaobing
    Bao, Yunguang
    Jiang, Mizu
    [J]. RHEUMATOLOGY, 2020, 59 (08) : 1826 - 1833
  • [8] Long-term consequences of Kawasaki disease - A 10- to 21-year follow-up study of 594 patients
    Kato, H
    Sugimura, T
    Akagi, T
    Sato, N
    Hashino, K
    Maeno, Y
    Kazue, T
    Eto, G
    Yamakawa, R
    [J]. CIRCULATION, 1996, 94 (06) : 1379 - 1385
  • [9] Analysis of Coronary Arterial Aneurysm Regression in Patients With Kawasaki Disease by Aneurysm Severity: Factors Associated With Regression
    Kato, Taichi
    Miura, Masaru
    Kobayashi, Tohru
    Kaneko, Tetsuji
    Fukushima, Naoya
    Suda, Kenji
    Maeda, Jun
    Shimoyama, Shinya
    Shiono, Junko
    Hirono, Keiichi
    Ikeda, Kazuyuki
    Sato, Seiichi
    Numano, Fujito
    Mitani, Yoshihide
    Waki, Kenji
    Ayusawa, Mamoru
    Fukazawa, Ryuji
    Fuse, Shigeto
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (03): : e022417
  • [10] Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial
    Kobayashi, Tohru
    Saji, Tsutomu
    Otani, Tetsuya
    Takeuchi, Kazuo
    Nakamura, Tetsuya
    Arakawa, Hirokazu
    Kato, Taichi
    Hara, Toshiro
    Hamaoka, Kenji
    Ogawa, Shunichi
    Miura, Masaru
    Nomura, Yuichi
    Fuse, Shigeto
    Ichida, Fukiko
    Seki, Mitsuru
    Fukazawa, Ryuji
    Ogawa, Chitose
    Furuno, Kenji
    Tokunaga, Hirohide
    Takatsuki, Shinichi
    Hara, Shinya
    Morikawa, Akihiro
    [J]. LANCET, 2012, 379 (9826) : 1613 - 1620